Sprycel dasatinib patent expiry generic?

Sprycel (dasatinib) isn’t protected by a single global “expiry date.” Patent protection for dasatinib exists in multiple patent families (composition of matter, salt/formulation patents, use-method patents, etc.) plus regulatory data exclusivities. Expiry dates vary by country and by which patent family or exclusivity is still in force.

If you want a concrete answer, tell me the country (e.g., United States, Europe, India, etc.). I can look up the current status and summarize:
- which patents or exclusivities are still active,
- the expected expiry dates for each,
- whether generic versions are or will be available in that market.

If you’d like to do it yourself, you can check:
- US: FDA Orange Book for dasatinib patents and exclusivities,
- Europe: European Patent Office / Espacenet and the EMA/market authorization data,
- Other countries: national patent databases (and local regulatory orange book equivalents).

Would you like me to pull specific expiry info for a particular country?